Tamoxifen is a medication primarily used to treat and prevent breast cancer. It works by blocking estrogen’s effects on breast tissue, making it a cornerstone treatment for the roughly 80% of breast cancers that are fueled by estrogen. It has four FDA-approved uses: treating metastatic breast cancer, preventing recurrence after early-stage breast cancer treatment, reducing the risk of invasive cancer after a diagnosis of ductal carcinoma in situ (DCIS), and lowering breast cancer risk in women who have never had the disease but are at high risk of developing it.
How Tamoxifen Works
Tamoxifen belongs to a class of drugs called selective estrogen receptor modulators, or SERMs. The key word is “selective.” In breast tissue, tamoxifen latches onto estrogen receptors and blocks estrogen from activating them, essentially starving hormone-sensitive cancer cells of the signal they need to grow. Early lab studies on human breast cancer cells showed that tamoxifen stopped cell replication entirely, and adding estrogen back reversed the effect, confirming that the drug works by competing directly with estrogen.
What makes tamoxifen selective is that it doesn’t block estrogen everywhere. In bone, the liver, and the uterine lining, it actually mimics estrogen rather than opposing it. This dual personality has real consequences, both helpful and harmful, depending on the tissue involved.
Treating Early-Stage Breast Cancer
The most common use of tamoxifen is as adjuvant therapy, meaning it’s taken after primary treatment (surgery, radiation, or chemotherapy) to reduce the chance that cancer comes back. It’s prescribed for people with early-stage, estrogen receptor-positive breast cancer. The standard course has traditionally been five years, but clinical evidence now supports extending treatment to ten years for certain patients.
In a major trial comparing the two durations, women who took tamoxifen for ten years had a 25% lower risk of their cancer returning between years 10 and 14, and a nearly 30% lower risk of dying from breast cancer, compared to those who stopped at five years. The benefit of extending treatment is strongest for people at higher risk of late recurrence, particularly those whose cancer had spread to lymph nodes or who had larger tumors.
For premenopausal women, tamoxifen is the standard of care because aromatase inhibitors, the other major class of hormone therapy, don’t work before menopause. Postmenopausal women are often switched to an aromatase inhibitor after a period on tamoxifen, though some stay on tamoxifen for the full course.
Preventing Breast Cancer in High-Risk Women
Tamoxifen is also approved for women who have never had breast cancer but face an elevated risk of developing it. The strongest risk factors include older age, a family history of breast cancer in a mother, sister, or daughter, and a prior breast biopsy showing atypical cell growth. Other contributing factors include early onset of menstruation, never having been pregnant, and having a first pregnancy later in life.
Risk is typically estimated using the National Cancer Institute’s Breast Cancer Risk Assessment Tool (sometimes called the Gail model), which combines these factors into a five-year risk score. The U.S. Preventive Services Task Force recommends that clinicians discuss tamoxifen with women who are at high risk for breast cancer and at low risk for the drug’s side effects. In general, the benefit-to-harm balance tends to be most favorable for women in their 40s with elevated cancer risk and no history of blood clots, and for women in their 50s who meet those same criteria and have had a hysterectomy (which eliminates the uterine risks described below).
Use After DCIS
Ductal carcinoma in situ is an early, non-invasive form of breast cancer confined to the milk ducts. After surgery and radiation for DCIS, tamoxifen can reduce the risk that invasive breast cancer develops later. It also lowers the chance of cancer appearing in the opposite breast, which is relevant for anyone with a prior breast cancer diagnosis.
Use in Men
Though breast cancer in men is rare, about 1% of all cases, tamoxifen is the preferred hormonal treatment when it occurs. ASCO guidelines strongly recommend tamoxifen for men with hormone receptor-positive breast cancer, with an initial duration of five years and the option to extend to ten years for those at high risk of recurrence. It’s also a first-line option for men with advanced or metastatic disease.
Adherence can be a challenge. Men on tamoxifen report notable rates of hot flashes, weight gain, and sexual dysfunction, and studies have found that men who are less consistent with their treatment have a greater risk of recurrence and death. Blood clot risk is also elevated, with more than 80% of clotting events occurring in the first 18 months of treatment.
Off-Label Uses
Beyond cancer, tamoxifen is sometimes prescribed for conditions unrelated to oncology. It can induce ovulation in women with infertility, functioning similarly to the more commonly known fertility drug clomiphene. It’s also used to treat gynecomastia (enlarged breast tissue in men) and associated breast pain. In young girls with McCune-Albright syndrome, a rare genetic condition that causes early puberty, tamoxifen has been shown to stop abnormal menstrual bleeding and stabilize bone development.
Side Effects and Risks
The most commonly reported side effects of tamoxifen are hot flashes, fatigue, and mood changes. Because tamoxifen acts like estrogen in the uterine lining, it can stimulate cell growth there. For women under 50, the increased risk of endometrial cancer is small and not statistically significant. The risk is more meaningful for older women, which is why those without a uterus have a more favorable benefit-to-harm profile when considering tamoxifen for prevention.
Blood clots are a more clearly established risk. The risk of deep vein thrombosis roughly doubles while actively taking tamoxifen. Importantly, this elevated risk disappears after stopping the drug, returning to baseline during follow-up.
Tamoxifen’s estrogen-mimicking effects on bone cut both ways depending on your menopausal status. In postmenopausal women, tamoxifen acts like estrogen on bone and can actually increase bone mass, which is a protective benefit. In premenopausal women, it may contribute to bone loss. This difference matters for long-term treatment planning, especially for younger patients on extended courses.
Antidepressants and Drug Interactions
Your body doesn’t use tamoxifen directly. It converts the drug into an active form called endoxifen, and that conversion depends on a specific liver enzyme. Certain medications, particularly some common antidepressants, can block this enzyme and dramatically reduce tamoxifen’s effectiveness.
This is especially relevant because antidepressants are frequently prescribed alongside tamoxifen, both for depression and as a way to manage the hot flashes tamoxifen itself causes. In one study, about 26% of tamoxifen patients were also taking an antidepressant that interfered with this conversion. The impact can be severe: among patients with normal drug metabolism, only 2% had inadequately low levels of the active drug when taking tamoxifen alone, but that number jumped to 62% when a strong-blocking antidepressant was added.
Clinical guidelines recommend avoiding strong blockers like fluoxetine (Prozac), paroxetine (Paxil), and bupropion (Wellbutrin) while on tamoxifen. Milder options like venlafaxine and desvenlafaxine are considered safer alternatives when an antidepressant is needed. If you’re prescribed both tamoxifen and an antidepressant, it’s worth confirming that the combination has been reviewed for this specific interaction.